{"id":172116,"date":"2025-11-05T03:20:46","date_gmt":"2025-11-05T08:20:46","guid":{"rendered":"https:\/\/44.250.171.167\/?p=172116"},"modified":"2025-11-05T03:20:46","modified_gmt":"2025-11-05T08:20:46","slug":"ajanta-pharma-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/ajanta-pharma-q2-fy26-earnings-results\/","title":{"rendered":"Ajanta Pharma\u00a0Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Ajanta Pharma, specializing in specialty pharmaceutical manufacturing and marketing, reported a solid Q2 FY26 performance.<\/p>\n<h2>Financial Overview:<\/h2>\n<ul>\n<li>Revenues increased 14.07% to \u20b91,354 crore from \u20b91,187 crore.<\/li>\n<li>Total expenses rose 17.16% to \u20b91,072 crore from \u20b9915 crore.<\/li>\n<li>Net <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/e3ae3f4a-9a49-4da7-97c8-29fdbdce241d.pdf\" target=\"_blank\" rel=\"noopener\">profit<\/a> increased 20.37% to \u20b9260 crore from \u20b9216 crore.<\/li>\n<li>Earnings per share grew 20.20% to \u20b920.83 from \u20b917.33.<\/li>\n<\/ul>\n<h2>Key Highlights:<\/h2>\n<ul>\n<li>EBITDA rose 5.4% year on year with steady margins, excluding forex impact.<\/li>\n<li>India branded generics expanded with volume growth of 115% and contribution of 39% from new product launches.<\/li>\n<li>US operations showed continued momentum with 4-5 product launches and market share gains.<\/li>\n<li>Africa tender business exhibited variability, expected to persist.<\/li>\n<\/ul>\n<h2>Strategic Focus:<\/h2>\n<ul>\n<li>Declared interim dividend of \u20b928 per share.<\/li>\n<li>Reinforced R&amp;D investments and pursued expansion in key markets.<\/li>\n<li>Forecasts sustained double-digit revenue growth supported by innovation and geographic growth.<\/li>\n<\/ul>\n<p>Ajanta\u2019s results reflect strong execution across markets and consistent financial growth.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/ajantpharm\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-172117\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT.png\" alt=\"Q2 FY26\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ajanta Pharma, specializing in specialty pharmaceutical manufacturing and marketing, reported a solid Q2 FY26 performance. Financial Overview: Revenues increased 14.07% to \u20b91,354 crore from \u20b91,187 crore. Total expenses rose 17.16% to \u20b91,072 crore from \u20b9915 crore. Net profit increased 20.37% to \u20b9260 crore from \u20b9216 crore. Earnings per share grew 20.20% to \u20b920.83 from \u20b917.33. [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":172117,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-172116","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169565,"url":"https:\/\/alphastreet.com\/india\/ajanta-pharma-ltd-q1-fy26-earnings-results-revenue-up-13-8-net-profit-up-3-7-yoy\/","url_meta":{"origin":172116,"position":0},"title":"Ajanta Pharma Ltd Q1 FY26 Earnings Results \u2013 Revenue Up 13.8%, Net Profit Up 3.7% YoY","author":"Divyansh_Kasana","date":"July 30, 2025","format":false,"excerpt":"Ajanta Pharma Limited is a specialty pharmaceutical company primarily engaged in the development, manufacturing, and marketing of high-quality finished dosage formulations. The company focuses on delivering innovative and affordable medicines across multiple therapeutic segments, strengthening its presence in domestic and international markets. Q1 FY26 Earnings Summary (Apr\u2013Jun 2025) Revenue: \u20b91,303\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":145168,"url":"https:\/\/alphastreet.com\/india\/earnings-ajanta-pharma-ltd-nse-ajantapharma-q4fy23-results-out-total-income-rises-2-1-yoy\/","url_meta":{"origin":172116,"position":1},"title":"Earnings | Ajanta Pharma Ltd. (NSE: AJANTAPHARMA): Q4FY23 Results Out; Total Income rises 2.1% YoY.","author":"Divyansh_Kasana","date":"May 5, 2023","format":false,"excerpt":"Ajanta Pharma is a leading Indian pharmaceutical company that specializes in the development, manufacturing, and marketing of high-quality specialty pharmaceutical finished dosages. Founded in 1973, the company has a strong focus on research and development and has invested heavily in building state-of-the-art facilities and advanced technologies. Ajanta Pharma has a\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172164,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":172116,"position":2},"title":"Aurobindo Pharma Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 6, 2025","format":false,"excerpt":"Aurobindo Pharma Ltd, a leading pharmaceutical company focused on active pharmaceutical ingredients and generic pharmaceuticals, reported a steady Q2FY26 financial performance with revenues rising 6.3% year-on-year to \u20b98,286 crore. Consolidated net profit increased by 3.8% to \u20b9848 crore, reflecting resilience in key markets such as the US and Europe. Key\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172155,"url":"https:\/\/alphastreet.com\/india\/sun-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":172116,"position":3},"title":"Sun Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 5, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172096,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":172116,"position":4},"title":"Gland Pharma\u00a0Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 4, 2025","format":false,"excerpt":"Gland Pharma, a Hyderabad-based global injectable-focused pharma company, reported steady financial growth in Q2 FY26 with strong performance in key international markets. Financial Highlights: Revenues increased 5.76% year on year to \u20b91,487 crore from \u20b91,406 crore. Total expenses rose 6.45% to \u20b91,287 crore from \u20b91,209 crore. Consolidated net profit rose\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172893,"url":"https:\/\/alphastreet.com\/india\/entero-healthcare-q2-fy26-earnings-results\/","url_meta":{"origin":172116,"position":5},"title":"Entero Healthcare Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"December 3, 2025","format":false,"excerpt":"Entero Healthcare Solutions Ltd, incorporated in 2018 and engaged in distribution and marketing of pharmaceutical and surgical products with allied services, reported robust financial results for Q2FY26. Financial Highlights: Revenues increased 20.75% year-on-year to \u20b91,571 crore from \u20b91,301 crore. Total expenses rose 19.98% to \u20b91,531 crore from \u20b91,276 crore. Consolidated\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=172116"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172116\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/172117"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=172116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=172116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=172116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}